Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Towards minimal residual disease-directed therapy in melanoma

ABSTRACT: Towards minimal residual disease-directed therapy in melanoma

PROVIDER: PRJNA477841 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7424160.fastq.gz	Fastqsanger.gz
	SRR7424170.fastq.gz	Fastqsanger.gz
	SRR7424180.fastq.gz	Fastqsanger.gz
	SRR7424190.fastq.gz	Fastqsanger.gz
	SRR7424200.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 865

Similar Datasets

Towards minimal residual disease-directed therapy in melanoma

Project description:Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics, yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD we applied single-cell RNA-sequencing to malignant cells isolated from BRAF-mutant patient-derived xenograft (PDX) melanoma cohorts exposed to concurrent RAF/MEK-inhibition.

2018-07-18 | GSE116237 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma

| PRJNA1014439 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

| PRJNA1014440 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

| PRJNA1014444 | ENA

Metabolic memory underlying minimal residual disease in breast cancer

Project description:<p>Tumor relapse from treatment-resistant cells (minimal residual disease, MRD) underlies most breast cancer related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive. Here we integrated multi-omics data from a tractable organoid system with a metabolic modelling approach to uncover the metabolic and regulatory idiosyncrasies of the MRD. We find that the resistant cells, despite their non-proliferative phenotype and the absence of oncogenic signaling, feature increased glycolysis and activity of certain urea cycle enzymes reminiscent of the tumor. This metabolic distinctiveness was also evident in a mouse model and in transcriptomic data from patients following neo-adjuvant therapy. We further identified a marked similarity in DNA methylation profiles between tumor and residual cells. Taken together, our data reveal a metabolic and epigenetic memory of the treatment-resistant cells. We further demonstrate that the memorized elevated glycolysis in MRD is crucial for their survival and can be targeted using a small molecule inhibitor without impacting normal cells. The metabolic aberrances of MRD thus offer new therapeutic opportunities for post-treatment care to prevent breast tumor recurrence.</p>

2021-09-14 | MTBLS1507 | MetaboLights

Search for New Biomarkers for the Monitoring of the Minimal Residual Disease of the Acute Lymphoblastic Leukemia.

Project description:The main goal of the research was to find some new biomarkers for the monitoring of the Minimal Residual Disease in Acute Lymphoblastic Leukemia patients. Keywords: Search for new Biomarkers

2008-03-15 | GSE10820 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Residual tumor cells which remain dormant after MYC inactivation in a primary MYC-HCC derived cell line.

2024-08-06 | GSE242745 | GEO

MITF-low melanoma subtype models in zebrafish reveal transcriptional sub-clusters and MITF-independent residual disease

Project description:The MITF-low melanoma transcriptional signature is predictive of poor outcome for patients but little is known about its biological signature. We used genetic models of zebrafish with low expression of mitfa (MITF-low) to study this biological subtype. Using genetic inhibition of MITF activity we discover minimal residual disease at the site of regression. We performed single cell RNA-seq (Smart-seq2) to characterise cells at the site of residual disease, and put in relation with primary tumours and recurring disease.

2019-10-09 | GSE136900 | GEO

Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy

Project description:We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy. Among the 16 B-ALL and 8 T-ALL subtypes identified by next generation sequencing, ETV6-RUNX1, high-hyperdiploid and DUX4-rearranged B-ALL had the best five-year event-free survival rates (95% to 98.4%); TCF3-PBX1, PAX5alt, T-cell, ETP, iAMP21, and hypodiploid ALL intermediate rates (80.0% to 88.2%); and BCR-ABL1, BCR-ABL1-like and ETV6-RUNX1-like and KMT2A-rearranged ALL the worst rates (64.1% to 76.2%). All but three of the 142 patients with day-8 blood MRD <0.01% remained in remission. Among new subtypes, intensified therapy based on day-15 MRDÃ¢Â‰Â¥1% improved outcome of DUX4-rearranged, BCR-ABL1-like, and ZNF384-rearranged ALL, and achievement of day-42 MRD<0.01% did not preclude relapse of PAX5alt, MEF2D-rearranged and ETV6-RUNX1-like ALL. Thus, new subtypes including DUX4-rearranged, PAX5alt, BCR-ABL1-like, ETV6-RUNX1-like, MEF2D-rearranged and ZNF384-rearranged ALL have important prognostic and therapeutic implications.

| EGAS00001005084 | EGA

Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia

Project description:GEP class prediction in association with CI-FISH (42 candidate genes) and patient MRD stratification Combined Interphase FISH (CI-FISH) for 42 candidate genes and Single Nucleotide Polymorphism (SNP) arrays were applied in a series of 51 T-ALL patients enrolled in Italy into the AIEOP-BFM ALL2000 protocol and stratified by Minimal Residual Disease (MRD). In 40 cases gene expression profiles (GEP) (Affymetrix HU-133 Plus 2.0 arrays) were available. This submission represents the gene expression component of the study

2013-11-05 | E-GEOD-39816 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data